Zevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Joshua Schafer Sells 10,500 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Joshua Schafer sold 10,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zevra Therapeutics Trading Up 1.0 %

ZVRA stock opened at $8.07 on Friday. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a 50 day moving average of $8.22 and a two-hundred day moving average of $8.04.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the business posted ($0.40) EPS. As a group, research analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZVRA. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and an average price target of $21.57.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Northern Trust Corp boosted its position in Zevra Therapeutics by 22.9% during the fourth quarter. Northern Trust Corp now owns 435,972 shares of the company’s stock valued at $3,636,000 after purchasing an additional 81,252 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Zevra Therapeutics during the fourth quarter valued at $716,000. Adage Capital Partners GP L.L.C. boosted its position in Zevra Therapeutics by 462.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after purchasing an additional 3,001,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Zevra Therapeutics by 51.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock valued at $172,000 after purchasing an additional 6,966 shares during the last quarter. Finally, Diadema Partners LP acquired a new stake in Zevra Therapeutics during the fourth quarter valued at $351,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.